|
1
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang S, Gao J, Lei Q, Rozengurt N,
Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, et
al: Prostate-specific deletion of the murine Pten tumor suppressor
gene leads to metastatic prostate cancer. Cancer Cell. 4:209–221.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Majumder PK, Yeh JJ, George DJ, Febbo PG,
Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, et al: Prostate
intraepithelial neoplasia induced by prostate restricted Akt
activation: the MPAKT model. Proc Natl Acad Sci USA. 100:7841–7846.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang CJ, Mulholland DJ, Valamehr B,
Mosessian S, Sellers WR and Wu H: PTEN nuclear localization is
regulated by oxidative stress and mediates p53-dependent tumor
suppression. Mol Cell Biol. 28:3281–3289. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Freeman DJ, Li AG, Wei G, Li HH, Kertesz
N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, et
al: PTEN tumor suppressor regulates p53 protein levels and activity
through phosphatase-dependent and -independent mechanisms. Cancer
Cell. 3:117–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vivanco I, Palaskas N, Tran C, Finn SP,
Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, et al:
Identification of the JNK signaling pathway as a functional target
of the tumor suppressor PTEN. Cancer Cell. 11:555–569. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
8
|
Schlaepfer IR, Rider L, Rodrigues LU,
Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM,
Eckel RH and Cramer SD: Lipid catabolism via CPT1 as a therapeutic
target for prostate cancer. Mol Cancer Ther. 13:2361–2371. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu X, Daniels G, Lee P and Monaco ME:
Lipid metabolism in prostate cancer. Am J Clin Exp Urol. 2:111–120.
2014.PubMed/NCBI
|
|
10
|
Van de Sande T, De Schrijver E, Heyns W,
Verhoeven G and Swinnen JV: Role of the phosphatidylinositol
3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty
acid synthase in LNCaP prostate cancer cells. Cancer Res.
62:642–646. 2002.PubMed/NCBI
|
|
11
|
Garcia-Cao I, Song MS, Hobbs RM, Laurent
G, Giorgi C, de Boer VC, Anastasiou D, Ito K, Sasaki AT, Rameh L,
et al: Systemic elevation of PTEN induces a tumor-suppressive
metabolic state. Cell. 149:49–62. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen L, Sun X, Fu Z, Yang G, Li J and Yao
L: The fundamental role of the p53 pathway in tumor metabolism and
its implication in tumor therapy. Clin Cancer Res. 18:1561–1567.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toren P, Kim S, Johnson F and Zoubeidi A:
Combined AKT and MEK pathway blockade in pre-clinical models of
enzalutamide-resistant prostate cancer. PLoS One. 11:e01528612016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Xiong H, Wu F, Zhang Y, Wang J,
Zhao L, Guo X, Chang LJ, Zhang Y, You MJ, et al: Hexokinase
2-mediated Warburg effect is required for PTEN- and
p53-deficiency-driven prostate cancer growth. Cell Rep.
8:1461–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kwabi-Addo B, Giri D, Schmidt K,
Podsypanina K, Parsons R, Greenberg N and Ittmann M:
Haploinsufficiency of the Pten tumor suppressor gene promotes
prostate cancer progression. Proc Natl Acad Sci USA.
98:11563–11568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fraser M, Zhao H, Luoto KR, Lundin C,
Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T and
Bristow RG: PTEN deletion in prostate cancer cells does not
associate with loss of RAD51 function: Implications for
radiotherapy and chemotherapy. Clin Cancer Res. 18:1015–1027. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tönjes M, Barbus S, Park YJ, Wang W,
Schlotter M, Lindroth AM, Pleier SV, Bai AHC, Karra D, Piro RM, et
al: BCAT1 promotes cell proliferation through amino acid catabolism
in gliomas carrying wild-type IDH1. Nat Med. 19:901–908. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Billingsley KL, Park JM, Josan S, Hurd R,
Mayer D, Spielman-Sun E, Nishimura DG, Brooks JD and Spielman D:
The feasibility of assessing branched-chain amino acid metabolism
in cellular models of prostate cancer with hyperpolarized
[1-(13)C]-ketoisocaproate. Magn Reson Imaging. 32:791–795. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yue S, Li J, Lee SY, Lee HJ, Shao T, Song
B, Cheng L, Masterson TA, Liu X, Ratliff TL and Cheng JX:
Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT
activation underlies human prostate cancer aggressiveness. Cell
Metab. 19:393–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cordero-Espinoza L and Hagen T: Increased
concentrations of fructose 2,6-bisphosphate contribute to the
Warburg effect in phosphatase and tensin homolog (PTEN)-deficient
cells. J Biol Chem. 288:36020–36028. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ,
Kim JW, Park SW and Kim KS: Androgen stimulates glycolysis for de
novo lipid synthesis by increasing the activities of hexokinase 2
and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in
prostate cancer cells. Biochem J. 433:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Phadngam S, Castiglioni A, Ferraresi A,
Morani F, Follo C and Isidoro C: PTEN dephosphorylates AKT to
prevent the expression of GLUT1 on plasmamembrane and to limit
glucose consumption in cancer cells. Oncotarget. 7:84999–85020.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Butler LM, Centenera MM and Swinnen JV:
Androgen control of lipid metabolism in prostate cancer: Novel
insights and future applications. Endocr Relat Cancer.
23:R219–R227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Horie Y, Suzuki A, Kataoka E, Sasaki T,
Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, et
al: Hepatocyte-specific Pten deficiency results in steatohepatitis
and hepatocellular carcinomas. J Clin Invest. 113:1774–1783. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen J, Guccini I, Di Mitri D, Brina D,
Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, et
al: Compartmentalized activities of the pyruvate dehydrogenase
complex sustain lipogenesis in prostate cancer. Nat Genet.
50:219–228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou W, Feng X, Ren C, Jiang X, Liu W,
Huang W, Liu Z, Li Z, Zeng L, Wang L, et al: Over-expression of
BCAT1, a c-Myc target gene, induces cell proliferation, migration
and invasion in nasopharyngeal carcinoma. Mol Cancer. 12:532013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu W, Shao Y and Peng Y: MicroRNA-218
inhibits tumor growth and increases chemosensitivity to CDDP
treatment by targeting BCAT1 in prostate cancer. Mol Carcinog.
56:1570–1577. 2017. View
Article : Google Scholar : PubMed/NCBI
|
